Free Trial

Orgenesis (ORGS) Competitors

Orgenesis logo
$1.41 -0.10 (-6.56%)
As of 07/8/2025 11:58 AM Eastern

ORGS vs. INKT, COEP, SXTC, SCYX, NRSN, TPST, CARA, TENX, LSTA, and CYTH

Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include MiNK Therapeutics (INKT), Coeptis Therapeutics (COEP), China SXT Pharmaceuticals (SXTC), SCYNEXIS (SCYX), NeuroSense Therapeutics (NRSN), Tempest Therapeutics (TPST), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), and Cyclo Therapeutics (CYTH). These companies are all part of the "pharmaceutical products" industry.

Orgenesis vs. Its Competitors

Orgenesis (NASDAQ:ORGS) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

MiNK Therapeutics has a consensus target price of $37.50, indicating a potential upside of 420.83%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MiNK Therapeutics is more favorable than Orgenesis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orgenesis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
MiNK Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Orgenesis and Orgenesis both had 1 articles in the media. Orgenesis' average media sentiment score of 0.00 equaled MiNK Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Orgenesis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
MiNK Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MiNK Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company Net Margins Return on Equity Return on Assets
Orgenesis-3,827.81% N/A -130.18%
MiNK Therapeutics N/A N/A -140.72%

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 5.7% of Orgenesis shares are held by insiders. Comparatively, 22.5% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Orgenesis has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.

MiNK Therapeutics has lower revenue, but higher earnings than Orgenesis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orgenesis$662K10.23-$55.36MN/AN/A
MiNK TherapeuticsN/AN/A-$9.51M-$2.52-2.86

Summary

MiNK Therapeutics beats Orgenesis on 6 of the 10 factors compared between the two stocks.

Get Orgenesis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORGS vs. The Competition

MetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.77M$820.66M$5.50B$8.94B
Dividend YieldN/A4.84%5.25%4.04%
P/E RatioN/A1.0926.9720.11
Price / Sales10.23230.52426.02119.76
Price / CashN/A23.4436.8257.86
Price / Book-0.216.137.985.56
Net Income-$55.36M-$27.85M$3.16B$248.40M
7 Day Performance-7.78%0.67%2.36%4.67%
1 Month Performance-37.84%8.48%2.15%6.64%
1 Year PerformanceN/A6.72%33.78%21.31%

Orgenesis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORGS
Orgenesis
1.8357 of 5 stars
$1.41
-6.6%
N/AN/A$6.77M$662K0.00150News Coverage
Gap Down
INKT
MiNK Therapeutics
2.6891 of 5 stars
$7.34
+5.2%
$37.50
+410.9%
-19.1%$27.82MN/A-2.9130News Coverage
Positive News
COEP
Coeptis Therapeutics
0.2015 of 5 stars
$7.80
+0.3%
N/A+45.3%$27.34MN/A-1.342News Coverage
SXTC
China SXT Pharmaceuticals
0.1511 of 5 stars
$1.73
+0.6%
N/A-79.1%$27.22M$1.82M0.0090News Coverage
SCYX
SCYNEXIS
0.258 of 5 stars
$0.67
-2.4%
N/A-63.0%$26.98M$3.75M-1.2060
NRSN
NeuroSense Therapeutics
1.7007 of 5 stars
$1.89
-0.5%
$14.00
+640.7%
+84.2%$25.97MN/A-3.5010
TPST
Tempest Therapeutics
1.7178 of 5 stars
$6.80
-1.4%
$30.00
+341.2%
-72.7%$25.41MN/A-0.3820
CARA
Cara Therapeutics
0.341 of 5 stars
N/AN/AN/A$24.33M$7.14M-0.2580Gap Down
High Trading Volume
TENX
Tenax Therapeutics
1.2571 of 5 stars
$5.76
-1.5%
$17.50
+203.8%
+81.7%$24.27MN/A-2.329
LSTA
Lisata Therapeutics
2.4885 of 5 stars
$2.90
+3.6%
$15.00
+417.2%
-16.2%$24.12M$1M-1.2630Gap Down
CYTH
Cyclo Therapeutics
N/A$0.72
flat
$0.95
+31.8%
N/A$23.72M$870.73K-0.809

Related Companies and Tools


This page (NASDAQ:ORGS) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners